ISDA: 6PKC

Deposition Date 2019-06-29

Release Date 2019-12-18

Last Version Date 2023-10-11

Entry Detail

PDB ID:

6PKC

Keywords:

TRANSCRIPTION

Title:

Inhibition of Human Menin by VTP-50469

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli BL21(DE3)

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.90 Å

R-Value Free:

0.20

R-Value Work:

0.16

R-Value Observed:

0.17

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Menin,Menin
Gene (Uniprot):MEN1
Mutagens:A5T
Chain IDs:A, B
Chain Length:490
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:O00255 Pfam ID:PF05053

Ligand Molecules

OP4

Primary Citation

A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.

Krivtsov, A.V, Evans, K, Gadrey, J.Y, Eschle, B.K, Hatton, C, Uckelmann, H.J, Ross, K.N, Perner, F, Olsen, S.N, Pritchard, T, McDermott, L, Jones, C.D, Jing, D, Braytee, A, Chacon, D, Earley, E, McKeever, B.M, Claremon, D, Gifford, A.J, Lee, H.J, Teicher, B.A, Pimanda, J.E, Beck, D, Perry, J.A, Smith, M.A, McGeehan, G.M, Lock, R.B, Armstrong, S.A.Show

Cancer Cell 36 660 673.e11 (2019)

PMID: 31821784 DOI: 10.1016/j.ccell.2019.11.001

Abstact

Inhibition of the Menin (MEN1) and MLL (MLL1, KMT2A) interaction is a potential therapeutic strategy for MLL-rearranged (MLL-r) leukemia. Structure-based design yielded the potent, highly selective, and orally bioavailable small-molecule inhibitor VTP50469. Cell lines carrying MLL rearrangements were selectively responsive to VTP50469. VTP50469 displaced Menin from protein complexes and inhibited chromatin occupancy of MLL at select genes. Loss of MLL binding led to changes in gene expression, differentiation, and apoptosis. Patient-derived xenograft (PDX) models derived from patients with either MLL-r acute myeloid leukemia or MLL-r acute lymphoblastic leukemia (ALL) showed dramatic reductions of leukemia burden when treated with VTP50469. Multiple mice engrafted with MLL-r ALL remained disease free for more than 1 year after treatment. These data support rapid translation of this approach to clinical trials.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form